title: [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
abstract: Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently Tagaserod an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.
authors.affiliation: Universidad de la Sabana.
authors.forename: Juan Guillermo
authors.initials: JG
authors.lastname: Ariza
authors.forename: Jairo Andrés
authors.initials: JA
authors.lastname: Martínez
mesh_terms: D006801:Humans; D007211:Indoles / Q000191:economics* / Q000627:therapeutic use*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000191:economics*; D017366:Serotonin Receptor Agonists / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod